Therapeutic drug monitoring of belatacept in kidney transplantation

Therapeutic Drug Monitoring

Volumn 37, Issue 5, 2015, Pages 560-567

  De Graav, Gretchen N ^a   Bergan, Stein ^b   Baan, Carla C ^a   Weimar, Willem ^a   Van Gelder, Teun ^a   Hesselink, Dennis A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Belatacept; Co stimulatory signal; Kidney; Therapeutic drug monitoring; Transplantation

Indexed keywords

BELATACEPT; ABATACEPT; CD86 ANTIGEN; CD86 PROTEIN, HUMAN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IMMUNOSUPPRESSIVE AGENT;

ASSAY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; HUMAN; IMMUNOGENICITY; KIDNEY TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; ADVERSE EFFECTS; ANTAGONISTS AND INHIBITORS; BLOOD; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; GLOMERULUS FILTRATION RATE; IMMUNOLOGY; TISSUE DISTRIBUTION;

ABATACEPT; ANTIGENS, CD86; CTLA-4 ANTIGEN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLOMERULAR FILTRATION RATE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; TISSUE DISTRIBUTION;

EID: 84941907662     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0000000000000179     Document Type: Review

References (36)

1. Larsen CP, Pearson TC, Adams AB, et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant. 2005;5:443-453.
2. Durrbach A, Pestana JM, Pearson T, et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant. 2010;10:547-557.
3. Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant. 2010;10:535-546.
4. Assessment Report Nulojix. London, UK: European Medicines Agency; 2011.
5. Bruce SP, Boyce EG. Update on abatacept: a selective costimulation modulator for rheumatoid arthritis. Ann Pharmacother. 2007;41:1153-1162.
6. Levisetti MG, Padrid PA, Szot GL, et al. Immunosuppressive effects of human CTLA4Ig in a non-human primate model of allogeneic pancreatic islet transplantation. J Immunol. 1997;159:5187-5191.
7. Kirk AD, Harlan DM, Armstrong NN, et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci U S A. 1997;94:8789-8794.
8. Schwartz RH. T cell anergy. Annu Rev Immunol. 2003;21:305-334.
9. Latek R, Fleener C, Lamian V, et al. Assessment of belatacept-mediated costimulation blockade through evaluation of CD80/86-receptor saturation. Transplantation. 2009;87:926-933.
10. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol. 2005;23:515-548.
11. Kim EJ, Kwun J, Gibby AC, et al. Costimulation blockade alters germinal center responses and prevents antibody-mediated rejection. Am J Transplant. 2014;14:59-69.
12. Scarsi M, Paolini L, Ricotta D, et al. Abatacept reduces levels of switched memory B cells, autoantibodies, and immunoglobulins in patients with rheumatoid arthritis. J Rheumatol. 2014;41:666-672.
13. Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med. 2006;355:1018-1028.
14. Vincenti F, Larsen C, Durrbach A, et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med. 2005;353:770-781.
15. Vincenti F, Blancho G, Durrbach A, et al. Five-year safety and efficacy of belatacept in renal transplantation. J Am Soc Nephrol. 2010;21:1587-1596.
16. Charpentier B, Medina Pestana JO, Del CRM, et al. Long-term exposure to belatacept in recipients of extended criteria donor kidneys. Am J Transplant. 2013;13:2884-2891.
17. Pestana JO, Grinyo JM, Vanrenterghem Y, et al. Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys. Am J Transplant. 2012;12:630-639.
18. Rostaing L, Massari P, Garcia VD, et al. Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study. Clin J Am Soc Nephrol. 2011;6:430-439.
19. Vanrenterghem Y, Bresnahan B, Campistol J, et al. Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies). Transplantation. 2011;91:976-983.
20. Grinyo J, Charpentier B, Pestana JM, et al. An integrated safety profile analysis of belatacept in kidney transplant recipients. Transplantation. 2010;90:1521-1527.
21. Matas AJ, Smith JM, Skeans MA, et al. OPTN/SRTR 2011 Annual data Report: kidney. Am J Transplant. 2013;13(suppl 1):11-46.
22. Myler HA, Phillips KR, Dong H, et al. Validation and life-cycle management of a quantitative ligand-binding assay for the measurement of Nulojix ((R)), a CTLA-4-Fc fusion protein, in renal and liver transplant patients. Bioanalysis. 2012;4:1215-1226.
23. BioLegend. Biotin Anti-human CD152 (CTLA-4) Product Data Sheet. San Diego, CA: BioLegend Inc.; 2014.
24. Zhou Z, Shen J, Hong Y, et al. Time-varying belatacept exposure and its relationship to efficacy/safety responses in kidney-transplant recipients. Clin Pharmacol Ther. 2012;92:251-257.
25. Data on File. NULO 125. Princeton, NJ: Bristol-Myers Squibb Company. Updated June 22, 2010. Accessed December 3, 2014.
26. Shen J, Townsend R, You X, et al. Pharmacokinetics, pharmacodynamics, and Immunogenicity of belatacept in adult kidney transplant recipients. Clin Drug Investig. 2013;34:117-126.
27. Goebl NA, Babbey CM, Datta-Mannan A, et al. Neonatal Fc receptor mediates internalization of Fc in transfected human endothelial cells. Mol Biol Cell. 2008;19:5490-5505.
28. Bristal-MyersSquibb. Nulojix: Highlights of Prescribing Information. Princeton, NJ: Bristol-Myers Squibb Company; 2013.
29. BMS FDA's Cardiovascular, Renal Drugs Advisory Committee. US Food and Drug Administration. Princeton, NJ: Bristol-Myers Squibb Company; 2010.
30. Moxness M, Tatarewicz S, Weeraratne D, et al. Immunogenicity testing by electrochemiluminescent detection for antibodies directed against therapeutic human monoclonal antibodies. Clin Chem. 2005;51:1983-1985.
31. Dutch Trial Register. Belatacept study. Amsterdam, the Netherlands: Dutch Trial Register (Nederlands Trial Register); 2013. Available at: http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=4242. Accessed January 12, 2015.
32. Roy A, Mould DR, Wang XF, et al. Modeling and simulation of abatacept exposure and interleukin-6 response in support of recommended doses for rheumatoid arthritis. J Clin Pharmacol. 2007;47:1408-1420.
33. Lo DJ, Weaver TA, Stempora L, et al. Selective targeting of human alloresponsive CD8+ effector memory T cells based on CD2 expression. Am J Transplant. 2011;11:22-33.
34. Xu H, Perez SD, Cheeseman J, et al. The allo- and viral-specific immunosuppressive effect of belatacept, but not tacrolimus, attenuates with progressive T cell maturation. Am J Transplant. 2014;14:319-332.
35. de Graav GN, Hesselink DA, Kraaijveld R, et al. CD28-positive T-lymphocytes of kidney-transplant candidates escape blockade by belatacept. 2013. European Society of Transplantation (ESOT): Basic Science Meeting 2013. Am J Transplant. 2013;14(S3):286. Abstract A71. Available at: http://onlinelibrary.wiley.com/doi/10.1111/ajt.12888/pdf. Accessed January 12, 2015.
36. Moreland LW, Alten R, Van den Bosch F, et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eightyfive days after the first infusion. Arthritis Rheum. 2002;46:1470-1479.